Recurrent and Nonrecurrent Condyloma Treatment

Phase 3TerminatedNCT01639638

Laboratorio Elea Phoenix S.A.132 enrolled

Overview

Treatment is considered successful if the difference in the response in the reduction of the affected area is above 30% for any of the doses compared to placebo Patients will be randomised to 1 of 3 treatment arms 1. Placebo 2. CIGB-300 - 5 mg 3. CIGB-300 - 15 mg A two week screening visit will take place to assess patient eligibility, at least 2 to 5 target lesions (area of the lesion between 20 to 80 mm2), should be identified. Patients included in the study will be randomly assigned to one of three study arms. Treatment consists of 3 perilesional applications at the base of the target lesion every 48 hours with a window of ±24hs. After each application the potential local and systemic adverse events will be identified and monitored. After the last application is made, weekly clinical evaluations for 3 weeks and then every two weeks, until week 12 will take place. At this time, clinical assessment of efficacy will be carried out that will define the response to treatment. After this visit, patients will be followed every 3 months until one year after the last treatment has been completed to confirm response and long-term security of the CIGB-300 application. At screening, at 2 and 8 weeks as well as at 6 and 12 months post-treatment blood studies will be conducted to assess the safety from the systemic point of view.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

132

Conditions

Recurrent Condyloma

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Informed consent signed by the patient 2. Women with clinical diagnosis of recurrent and non recurrent genital condyloma 3. Presence of a condylomatous lesion or area of external confluent condylomatous lesions of not less than 20 or more than 80 mm2 4. The number of warts should be between 2 and 20 5. External genital warts or in perigenital regions 6. Negative pregnancy test 7. Age between 18 and 65 years inclusive Exclusion Criteria: 1. Having received surgery treatment, ablative or immunomodulator treatment during the 30 days prior to inclusion 2. Presence of genital warts only located in the cervix, vagina, bladder or rectum 3. Pregnancy and lactation 4. Patients of childbearing age who are not using an adequate contraception method during treatment to prevent pregnancy. 5. Inadequately controlled chronic diseases (hypertension, diabetes, chronic kidney failure, heart failure, hyperthyroidism, malignant neoplasms, epilepsy, severe mental depression) 6. Patients with previous diagnosis of bleeding disorders and other chronic blood disorders (von Willebrand disease, haemophilia, leukaemia) or use of anticoagulants within 30 days before the study 7. Current genital herpes, which requires application of topical antivirals 8. Immunosuppressive disease, current intake of immunosuppressive/ immunomodulatory drugs within 30 days before the study. 9. Autoimmune Diseases (Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Diabetes) 10. Severe allergy history as urticaria, dermatitis or persistent bronchitis and bronchial asthma 11. Febrile illness (temperature greater than 38ºC) at the time or within 24 hours prior to administration of the product or suspected acute infectious disease by clinical examination 12. Diseases that compromise the patient's consciousness or the ability to give informed consent or to collaborate in the study 13. Concomitant skin lesions that prevent the administration of condylomatous lesions at the proposed site 14. Participating in another clinical trial

Outcomes

Primary Outcomes

Number of patients with complete response of target lesion in each study group

Time frame: Up to one year

Number of patients with adverse events during the application of the study drug

Time frame: Up to one year

Secondary Outcomes

Effect of the perilesional application of CIGB300 in the reduction in the number and area of genital warts lesions treated directly

Time frame: Up to one year

Locoregional effect of CIGB300 by assessing the area and number of genital warts lesions not directly treated

Time frame: Up to one year

Effect of CIGB300 to avoid recurrence of the lesions

Time frame: Up to one year

Optimal dose, in comparison with placebo

Time frame: Up to one year

Number of patients with adverse events

Time frame: Up to one year

Recurrent and Nonrecurrent Condyloma Treatment

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes